Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) has earned an average rating of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $32.00.

ODTX has been the topic of a number of research analyst reports. Oppenheimer reiterated an “outperform” rating and set a $40.00 target price on shares of Odyssey Therapeutics in a research report on Thursday, June 18th. JPMorgan Chase & Co. assumed coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “overweight” rating and a $26.00 price objective for the company. TD Cowen started coverage on Odyssey Therapeutics in a report on Tuesday, June 2nd. They issued a “buy” rating for the company. Cantor Fitzgerald initiated coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “overweight” rating on the stock. Finally, Wall Street Zen cut shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 20th.

Insider Activity

In other Odyssey Therapeutics news, Director Nan (Ln) Li acquired 1,111,111 shares of the stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $18.00 per share, with a total value of $19,999,998.00. Following the transaction, the director owned 3,333,516 shares of the company’s stock, valued at approximately $60,003,288. This trade represents a 50.00% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Dimension Capital Ii, L.P. acquired 1,111,111 shares of the company’s stock in a transaction on Friday, May 8th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $19,999,998.00. Following the completion of the purchase, the director owned 3,333,516 shares of the company’s stock, valued at $60,003,288. This trade represents a 50.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 4,183,777 shares of company stock worth $75,319,986 over the last 90 days.

Odyssey Therapeutics Stock Performance

ODTX stock opened at $18.22 on Wednesday. Odyssey Therapeutics has a twelve month low of $15.10 and a twelve month high of $20.30. The business’s 50 day moving average is $17.41.

Odyssey Therapeutics (NASDAQ:ODTX) last issued its earnings results on Wednesday, June 17th. The company reported ($6.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($5.46).